Fusilev patents expiration

FUSILEV Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6500829 ACROTECH Substantially pure diastereoisomers of tetrahydrofolate derivatives
Mar, 2022

(1 year, 6 months ago)

Fusilev is owned by Acrotech.

Fusilev contains Levoleucovorin Calcium.

Fusilev has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Fusilev are:

  • US6500829

Fusilev was authorised for market use on 07 March, 2008.

Fusilev is available in powder;intravenous, solution;intravenous dosage forms.

The generics of Fusilev are possible to be released after 07 March, 2022.

Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient

Market Authorisation Date: 07 March, 2008

Treatment: NA


How can I launch a generic of FUSILEV before it's drug patent expiration?
More Information on Dosage

FUSILEV family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic